ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A. Matulonis, Julie Lee, Brian Lasonde, William P. Tew, Afra Yehwalashet, Daniela Matei, Kian Behbakht, Jill Grothusen, Gini Fleming, Nita K. Lee, Jamie Arnott, Mark R. Bray, Graham Fletcher, RVolume:
49
Year:
2013
Language:
english
DOI:
10.1016/j.ejca.2012.07.020
File:
PDF, 757 KB
english, 2013